Value
3.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 6.0 |
RYTM · Why this verdict
Why Rhythm Pharmaceuticals (RYTM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue grew 84% year-over-year, reflecting accelerating adoption of setmelanotide, while analyst price targets imply 55% upside from current levels, suggesting significant commercial potential is not yet priced into the stock. Growth breakdown | Revenue growth remains above 40% year-over-year for at least 3 of the next 4 quarters as patient adoption expands. | →Stable |
| CounterApproximately 100% of revenue is derived from a single drug, setmelanotide, so any safety signal, label restriction, or reimbursement headwind could eliminate the entire revenue base. | ||
A volume surge of 3.6 times average on an up move, combined with rising on-balance volume and an improving MACD, suggests institutional accumulation is occurring despite the stock trading below its 200-day moving average. Momentum breakdown | Price rises above $100, more than 11% above the current $89.70, on sustained volume within the next 12 months. | →Stable |
| CounterVolume spikes in small biotech names frequently precede sharp reversals, and the stock is still in a death-cross recovery pattern with RSI at only 50. | ||
With a potential upside of 39.4% to the analyst consensus target of $125 versus a downside of only 9.7% to the stop, the risk-reward ratio of 5.6 to 1 is exceptional for a biotech recovery name. Targets | Analyst target price rises above $130 or current price rises above $110, more than 22% above the current $89.70, within 12 months. | →Stable |
| CounterThe quality score sits below the minimum floor at 3.5 out of 10, with the company burning cash at 69% of revenue, meaning the asymmetric upside reflects lottery-ticket pricing rather than fundamental value. | ||
Free cash flow is negative at 69% of revenue, and the company is pre-profitability on all key income metrics, meaning continued operations depend on either capital markets access or achieving commercial scale rapidly enough to self-fund. Quality breakdown | Cash runway extends beyond 18 months with current balance sheet, and quarterly cash burn decreases by at least 10% year-over-year as revenue scales. | →Stable |
| CounterThe company has a high current ratio and access to capital markets, suggesting near-term liquidity risk is manageable even if the burn rate is uncomfortable. | ||
Revenue grew 84% year-over-year, reflecting accelerating adoption of setmelanotide, while analyst price targets imply 55% upside from current levels, suggesting significant commercial potential is not yet priced into the stock.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 40% year-over-year for at least 3 of the next 4 quarters as patient adoption expands.
CounterApproximately 100% of revenue is derived from a single drug, setmelanotide, so any safety signal, label restriction, or reimbursement headwind could eliminate the entire revenue base.
A volume surge of 3.6 times average on an up move, combined with rising on-balance volume and an improving MACD, suggests institutional accumulation is occurring despite the stock trading below its 200-day moving average.
→StableMomentum breakdown
- Expectation
- Price rises above $100, more than 11% above the current $89.70, on sustained volume within the next 12 months.
CounterVolume spikes in small biotech names frequently precede sharp reversals, and the stock is still in a death-cross recovery pattern with RSI at only 50.
With a potential upside of 39.4% to the analyst consensus target of $125 versus a downside of only 9.7% to the stop, the risk-reward ratio of 5.6 to 1 is exceptional for a biotech recovery name.
→StableTargets
- Expectation
- Analyst target price rises above $130 or current price rises above $110, more than 22% above the current $89.70, within 12 months.
CounterThe quality score sits below the minimum floor at 3.5 out of 10, with the company burning cash at 69% of revenue, meaning the asymmetric upside reflects lottery-ticket pricing rather than fundamental value.
Free cash flow is negative at 69% of revenue, and the company is pre-profitability on all key income metrics, meaning continued operations depend on either capital markets access or achieving commercial scale rapidly enough to self-fund.
→StableQuality breakdown
- Expectation
- Cash runway extends beyond 18 months with current balance sheet, and quarterly cash burn decreases by at least 10% year-over-year as revenue scales.
CounterThe company has a high current ratio and access to capital markets, suggesting near-term liquidity risk is manageable even if the burn rate is uncomfortable.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Rhythm Pharmaceuticals' 84% year-over-year revenue growth and 39% analyst upside target reflect a high-conviction commercial ramp for setmelanotide, but single-product concentration and below-floor quality scores make this a speculative position requiring close monitoring.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.8 |
| FCF quality | 0.0 |
| Moat | 6.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -69% of revenue
- ▸Rule of 40: 14 (fail)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 84% YoY
Momentum
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.1 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 2.7 |
- ▸Overbought (RSI 98)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 98 (late-cycle distribution risk)
Sentiment
7.4/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.6 |
| Price target | 7.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 22%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $4,140,027 (0.053% of mkt cap)
Peer rank
2.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.6 |
| quality rank | 0.1 |
| growth rank | 7.9 |
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.2 |
| support resistance | 0.1 |
| 52w position | 8.7 |
Risk (lower is worse)
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.1 |
| days to cover | 0.0 |
| volatility | 1.1 |
| put call | 9.8 |
| implied vol | 2.7 |
| beta | 3.7 |
| debt equity | 8.1 |
- ▸High IV: 64%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.8 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- MOMENTUM:6.7>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.7<1.5@spot
Warning (2)
- DEATH_CROSS:momentum=6.7>=5.0 recovering
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
0.66
Upside
+9.9%
Downside
15.0%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 98
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.7<1.5@spot.
The strongest dimensions are Growth at 10.0, Sentiment at 7.4, and Momentum at 6.7; the weakest are Peer rank at 2.4, Technical at 3.3, and Catalyst at 3.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.66 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Setmelanotide Revenue Ramp
Trip ifRevenue growth falls below 20% year-over-year for at least 2 consecutive quarters.
- P2Momentum Surge Signal
Trip ifPrice drops below $83, more than 7% below the current $89.70, on volume more than 2 times the 20-day average.
- P3Analyst Conviction Asymmetry
Trip ifAnalyst consensus target falls below $100, more than 20% below current estimates, following a label or reimbursement setback.
- P4Cash Burn Sustainability Risk
Trip ifCash runway decreases to less than 12 months or quarterly cash burn increases by more than 25% year-over-year.